VINC Insider Trading Activity and SEC Form 4 Filings
VINC insider trading summary
No open-market insider purchases or sales of Vincerx Pharma, Inc. (VINC) have been reported on SEC Form 4 in the past 12 months.
Latest VINC insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Aug 11, 2023 | Alexander A. Seelenberger | See Remarks | Buy | $10K (10,500 @ $0.95) |
| Aug 10, 2023 | Ahmed MD Hamdy | See Remarks | Buy | $5K (5,400 @ $0.96) |
| Aug 10, 2023 | Raquel E. Izumi | See Remarks | Buy | $3K (3,440 @ $0.93) |
| Aug 10, 2023 | Tom C Thomas | See Remarks | Buy | $5K (5,000 @ $0.95) |
| Aug 9, 2023 | Ahmed MD Hamdy | See Remarks | Buy | $16K (16,900 @ $0.95) |
| Aug 9, 2023 | Raquel E. Izumi | See Remarks | Buy | $12K (13,036 @ $0.90) |
| Dec 14, 2022 | Tom C Thomas | See Remarks | Buy | $6K (7,000 @ $0.83) |
| Dec 14, 2022 | Ahmed MD Hamdy | Chief Executive Officer | Buy | $31K (35,280 @ $0.87) |
| Dec 14, 2022 | Raquel E. Izumi | See Remarks | Buy | $25K (28,738 @ $0.88) |
| Aug 25, 2022 | Christopher P. Lowe | Director | Buy | $19K (11,600 @ $1.65) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.